Key facts
- Character Biosciences’s last known valuation is $203.0M (Sep 2025).
- It has raised $136.9M across 2 recorded rounds; the latest was Early Stage VC ($8.9M) in Sep 2025.
- Notable investors include Industry Ventures, Innovation Endeavors, Catalio Capital Management, S32, Duke Capital Partners — 18 tracked in total.
- Character Biosciences has filed 2 Form Ds with the SEC, most recently Sep 2025 ($8.9M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Character Biosciences
Funding rounds
2 roundsAbout Character Biosciences
Developer of precision medicine designed to transform drug development for progressive, polygenic diseases. The company integrates genomics, clinical data, and AI-driven modeling to develop targeted therapies for dry age-related macular degeneration and primary open-angle glaucoma, enabling clinicians, researchers, and patients to create effective treatments, improve prediction of disease course, and focus therapies on individual patient needs.
- Sector
- Healthcare
- HQ
- Jersey City, NJ, United States
- Founded
- 2018
- Employees
- 48
- Website
- characterbio.com/
- Ownership
- Privately Held (backing)
Character Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Character Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Character Biosciences in its N-PORT filings yet. We sweep new filings monthly.